Episode 128: Debate of the Decade: RCTs in the Era of Precision Oncology
Healthcare Unfiltered
00:00
The Importance of Comparative Studies in Oncology
Vivek: I think we can agree that a matinev for CML, just like BEP for testicular cancer, are clear outliers. But again, those are exceptions. Most cancer medicines are approved now with no proven increase in overall survival or quality of life. We're not doing a good enough job for our patients, Vivek says.
Play episode from 27:18
Transcript
